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Abstract
Background & Aims: Thrombocytopaenia and hypoalbuminaemia are surrogate markers for portal hypertension and hepatic
synthetic dysfunction respectively. Patients infected with hepatitis C virus (HCV) with these surrogates have reduced likelihood of
sustained virologic response and increased risk for hepatic decompensation or death when treated with peginterferon/ribavirin plus
either telaprevir or boceprevir. Methods: We conducted a post-hoc analysis of the TURQUOISE-II clinical trial in patients with
cirrhosis to examine the impact of these surrogates on efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir
with ribavirin. Results: Of 380 genotype 1-infected patients in TURQUOISE-II, 104 had either a platelet count <100 9 109/L
or albumin <3.5 g/dl. Sustained virologic response rates were 89 and 97% in patients with thrombocytopaenia, and 84 and
89% in patients with hypoalbuminaemia after 12 and 24 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir with rib-
avirin respectively. These rates were similar to those observed in the overall study population (92 and 97% for 12 and
24 weeks). HCV genotype 1a-infected patients with thrombocytopaenia or hypoalbuminaemia had higher response rates
when treated for 24 weeks, whereas only 1 of 35 genotype 1b patients did not achieve a sustained virologic response.
Adverse event rates and discontinuations because of adverse events were low. Conclusions: The findings of these analyses
support the use of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in these subpopulations with cirrhosis.
Genotype 1a-infected patients with indicators of portal hypertension may benefit from a 24-week treatment duration.
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In patients with cirrhosis, thrombocytopaenia is a surro-
gate for portal hypertension and hypoalbuminaemia is a
surrogate for diminished hepatic synthetic function.
Although hepatitis C virus (HCV) triple therapy with
first-generation protease inhibitors, boceprevir or telapre-
vir, modestly improved sustained virologic response
(SVR) rates compared to peginterferon plus ribavirin
(RBV), the adverse event (AE) profile was less favourable
with an increased risk of rash and potentiation of anaemia
(1–5). In the Compassionate Use of Protease Inhibitors in
viral C Cirrhosis (CUPIC) observational study, baseline
platelet count ≤100 9 109/L and serum albumin level
<3.5 g/dl were associated with an increased risk of serious
complications including hepatic decompensation, bacte-
rial infections, and death (6, 7). Treatment efficacy was
particularly poor in patients with prior null response to
peginterferon/RBV therapy (<20%) suggesting that
patients with these characteristics should not be treated
with boceprevir or telaprevir triple therapy (6, 7).
Interferon-free treatment regimens with two or more
direct-acting antiviral agents have recently been
approved to treat HCV-infected patients with and with-
out cirrhosis. One such all-oral regimen combines three
direct-acting antivirals (3D): ombitasvir (OBV; an
NS5A inhibitor); paritaprevir [PTV; an NS3/4A protease
inhibitor dosed with ritonavir (r)]; and dasabuvir (DSV;
an NS5B RNA polymerase inhibitor). In phase 3 studies
among HCV genotype (GT) 1-infected patients without
cirrhosis, the 3D regimen with RBV yielded SVR rates of
96–100% in treatment-na€ıve and peginterferon/RBV
treatment-experienced patients with low rates of
treatment discontinuation secondary to AEs (8–11). The
efficacy and safety of this regimen among patients with
cirrhosis and surrogate markers of portal hypertension
and poor synthetic function were explored in this
post-hoc analysis of the TURQUOISE-II trial.
Patients and methods
The phase 3 TURQUOISE-II study evaluated the safety
and efficacy of the 3D regimen with RBV in 380 HCV
GT1-infected, treatment-na€ıve and treatment-experi-
enced patients with compensated cirrhosis including
prior peginterferon/RBV null responders (12). Patients
were randomized to receive coformulated OBV/PTV/r
(25/150/100 mg QD), DSV (250 mg BID), and weight-
based RBV (1000 mg or 1200 mg total daily dose BID)
for 12 or 24 weeks. Baseline demographic and disease
characteristics of those enrolled in this study have been
described previously (12).
In this post-hoc analysis, patients with baseline surro-
gate markers of portal hypertension (platelet count
<100 9 109/L) and/or impaired liver function (serum
albumin level <3.5 g/dl) were compared to patients
without these characteristics. At baseline, 104 patients
(27.4%) had either platelet count <100 9 109/L
(N = 78, 20.5%) or albumin levels <3.5 g/dl (N = 43,
11.3%). Seventeen (4.5%) patients met both criteria for
thrombocytopaenia and hypoalbuminaemia at baseline.
Table S1 lists the characteristics for the patients within
these subgroups. The majority of patients were white
males, infected with HCV GT1a, and most had previ-
ously failed peginterferon/RBV treatment. Notably,
there were a larger proportion of patients with prior
peginterferon/RBV null response among those with
baseline thrombocytopaenia (47.4%) compared to those
with baseline hypoalbuminaemia (34.9%).
Results
Rates of sustained virologic response at week 12 post-
treatment (SVR12) in the overall population were 91.8
and 96.5% in the 12- and 24-week treatment groups
respectively (12). These differences were not statistically
different. Patients with GT1a infection and a history of
prior null response had higher SVR rates in the 24-week
group than the 12-week group (93 vs 80%). Among the
78 patients with baseline platelet counts <100 9 109/L,
SVR12 rates were 89% and 97% in those receiving 12-
or 24-weeks of 3D + RBV respectively (Fig. 1). In the 43
patients with baseline albumin levels <3.5 g/dl, SVR12
rates were 84% and 89% when treated for 12 or
24 weeks respectively. These SVR12 rates were not sta-
tistically different than those in patients without throm-
bocytopaenia or hypoalbuminaemia at baseline. Among
patients with both surrogate markers, 8/10 and 7/7
patients receiving 12 or 24 weeks of therapy achieved
SVR12 respectively. In patients with either thrombocy-
topaenia or hypoalbuminaemia, SVR12 was achieved in
88% of patients receiving 12-week treatment and 93%
receiving 24-week treatment. Although SVR rates were
numerically higher among patients with markers of por-
tal hypertension and decreased synthetic function who
were treated for 24 weeks than 12 weeks, wide confi-
dence intervals were observed because of small sample
Key points box
• Hepatitis C-infected patients with cirrhosis and
thrombocytopaenia or hypoalbuminaemia are at
increased risk for serious complications with inter-
feron-based treatments.
• Ombitasvir/paritaprevir/r and dasabuvir with rib-
avirin for 12 or 24 weeks achieved high sustained
virologic response rates in cirrhotic patients with
thrombocytopaenia and hypoalbuminaemia that
were not statistically different than in patients with-
out these indicators of portal hypertension.
• Baseline median platelet counts and albumin did
not differ between patients who did or did not
achieve a sustained virologic response.
• The safety profiles were similar in patients with
and without surrogate markers of more advanced
liver disease, except for indirect hyperbilirubinaemia.
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sizes. Eleven (14.1%) patients with baseline thrombocy-
topaenia and 10 (23.3%) patients with baseline hypoal-
buminaemia had oesophageal varices or a history of
varices at baseline, one of whom did not achieve SVR.
Baseline characteristics for patients not achieving SVR12
are presented in Table S2.
Examining HCV subgenotypes, patients with GT1a
infection and platelets <100 9 109/L had SVR12 rates
of 87 and 96% when treated for 12 or 24 weeks respec-
tively (Table S3). The SVR12 rate also increased for
GT1a patients with albumin <3.5 g/dl with longer treat-
ment duration, 75% for 12-week treatment vs 88% for
24 weeks. Among 39 GT1a patients with either throm-
bocytopaenia or hypoalbuminaemia receiving 24 weeks
of 3D + RBV, two patients prematurely discontinued
treatment, and 1 (2.6%) relapsed. Of 35 patients
infected with GT1b, one patient with low platelets expe-
rienced relapse. All GT1b-infected patients with low
albumin achieved SVR12 (Table S3).
For all patients in TURQUOISE-II, median platelet
counts did not differ significantly between patients who
did or did not achieve SVR12 (141 9 109/L vs
143 9 109/L respectively; Fig. S1a). Similarly, the med-
ian baseline albumin did not significantly differ between
patients who did or did not achieve SVR12 (4.0 vs
3.9 g/dl respectively; Fig. S1b).
Fatigue, headache and nausea were the most common
treatment-emergent AEs in the overall population and
the majority of AEs were mild or moderate in severity.
No treatment-emergent deaths occurred, nor were
marked differences observed in rates of AEs comparing
either subgroup to the overall population (Table 1).
Among the 21 patients in TURQUOISE-II who experi-
enced serious AEs, eight (38%) had surrogate markers
of either portal hypertension or impaired liver function.
Four of these eight had events attributed to 3D and/or
RBV including chronic obstructive pulmonary disease,
cellulitis, and two events of anaemia. Grade 3 total
bilirubin abnormalities were more common in patients
with baseline thrombocytopaenia and hypoalbu-
minaemia compared to the overall population (15.4 and
18.6% vs 9.7% respectively); however, the baseline mean
total bilirubin levels were higher in patients with throm-
bocytopaenia or with hypoalbuminaemia than without
(1.08 and 1.13 mg/dl vs 0.82 mg/dl respectively). These
laboratory elevations mostly comprised indirect biliru-
bin and were not associated with aminotransferase ele-
vations. No patient with baseline hypoalbuminaemia
and one patient with baseline thrombocytopaenia had a
grade 3 alanine aminotransferase elevation.
Thirty-four (9.0%) patients in TURQUOISE-II
reduced RBV dose because of anaemia-related AEs
including 9 (11.5%) with thrombocytopaenia and 4
Fig. 1. SVR12 rates for patients with baseline platelet count < or
≥100 9 109/L, albumin < or ≥3.5 g/dl, and with platelet count
<100 9 109/L and albumin <3.5 g/dl. Whiskers indicate 95% con-
fidence intervals. SVR12, sustained virologic response 12 weeks
after the last dose of study drug.
Table 1. Common treatment-emergent adverse events occurring












Any AE 347 (91.3) 73 (93.6) 38 (88.4)
Any serious AE 21 (5.5) 5 (6.4) 6 (14.0)
AE leading to
discontinuation
8 (2.1) 2 (2.6) 2 (4.7)
Fatigue 148 (38.9) 30 (38.5) 17 (39.5)
Headache 111 (29.2) 23 (29.5) 12 (27.9)
Nausea 72 (18.9) 16 (20.5) 6 (14.0)
Pruritus 71 (18.7) 18 (23.1) 10 (23.3)
Insomnia 63 (16.6) 14 (17.9) 8 (18.6)
Diarrhoea 59 (15.5) 14 (17.9) 10 (23.3)
Asthenia 51 (13.4) 6 (7.7) 2 (4.7)
Rash 48 (12.6) 9 (11.5) 5 (11.6)
Cough 43 (11.3) 9 (11.5) 4 (9.3)
Irritability 36 (9.5) 8 (10.3) 2 (4.7)
Anaemia 34 (8.9) 10 (12.8) 4 (9.3)
Dyspnoea 33 (8.7) 9 (11.5) 5 (11.6)
Decreased
appetite
26 (6.9) 5 (6.4) 5 (11.6)
Peripheral
oedema




34 (8.9) 6 (7.7) 4 (9.3)
Haemoglobin
G3
4 (1.1) 3 (3.8)* 1 (2.3)*
Total bilirubin
G3
37 (9.7) 12 (15.4) 8 (18.6)
ALT G3 6 (1.6) 1 (2.2) 0
AST G3 1 (0.3) 0 0
*One patient with a grade 3 decline in haemoglobin had baseline plate-
let count <100 9 109/L and albumin <3.5 g/dl.
G2 haemoglobin is <10-8 g/dl, G3 haemoglobin is <8 g/dl, G3 ALT and
AST are > 5 9 ULN.
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; G2, grade 2; G3, grade 3; ULN, upper limit of normal.
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(9.3%) with hypoalbuminaemia at baseline; all achieved
SVR. One patient with thrombocytopaenia, and one
patient with both thrombocytopaenia and hypoalbu-
minaemia required a transfusion; no patient received
erythropoietin.
Discussion
TURQUOISE-II included a sufficient number of HCV
GT1-infected patients with cirrhosis to support this
post-hoc analysis focusing on patients with moderate
thrombocytopaenia and/or hypoalbuminaemia at study
entry. Sustained virologic response rates in those with
markers of portal hypertension ranged from 84 to 97%.
Our analysis suggests that patients with cirrhosis and
moderate thrombocytopaenia, hypoalbuminaemia, or
the combination of both does not significantly impact
the efficacy or safety of 3D + RBV. Importantly, these
results were achieved despite a high representation of
HCV GT1a infection and prior null response to pegin-
terferon/RBV. Nevertheless, there was a trend towards
higher SVR12 rates in GT1a-infected patients treated for
24 weeks, suggesting that this duration may be consid-
ered for those with low platelets or albumin.
Efficacy and safety data are limited in patients with
cirrhosis, particularly in peginterferon/RBV prior null
responders and in those with thrombocytopaenia or
hypoalbuminaemia. In the CUPIC observational trial,
predictors of lower efficacy included prior null response,
GT1a infection, and a baseline platelet count
<100 9 109/L (6). Efficacy rates among treatment-expe-
rienced patients with compensated cirrhosis were 54–
74% among prior relapsers, and 0–19% among prior null
responders (7). In TURQUOISE-II, there were no signifi-
cant differences in SVR rates by treatment history in the
subgroups of patients with thrombocytopaenia or
hypoalbuminaemia at baseline (Table S3).
Published data with interferon-free regimens in
patients with cirrhosis are limited, particularly in prior
null responders and in those with surrogate markers of
portal hypertension or decreased synthetic function. In a
study of previously treated patients with cirrhosis, the
combination of ledipasvir and sofosbuvir yielded SVR
rates of 82–86% in the 12-week arm and 100% in the 24-
week arm (13). The addition of ribavirin to sofosbuvir
and ledipasvir for 12 weeks increased SVR rates in treat-
ment-experienced patients with compensated cirrhosis;
however, SVR rates are unknown for prior null respon-
ders and/or small sample sizes limit conclusions about
patients with baseline thrombocytopaenia or baseline
hypoalbuminaemia (13–16). In a phase 2 trial of grazo-
previr plus elbasvir, SVR rates of 92% were achieved in
prior null responders with cirrhosis, and SVR rates were
72% among 25 patients with baseline platelet counts
<90 9 109/L (17). A response rate of 71% was observed
in GT1b-infected patients with baseline platelet count
<90 9 109/L receiving the combination of daclatasvir
and asunaprevir (18). By comparison, 94% of GT1b-in-
fected patients with baseline platelet count <90 9 109/L
achieved SVR12 in TURQUOISE-II (12). The safety pro-
files of these interferon-free regimens in patients with
cirrhosis have generally been favourable with low rates of
treatment discontinuations related to AEs (12–18).
The safety profile of the 3D + RBV regimen was simi-
lar in patients with cirrhosis with and without the surro-
gate markers of more advanced liver disease, although
higher rates of hyperbilirubinaemia were observed
mainly comprising indirect bilirubin and not coinciding
with aminotransferase elevations. Within these sub-
groups, RBV dose adjustment for anaemia-related AEs
occurred at similar rates to those observed in the entire
study population. In contrast, patients in the CUPIC
trial with platelet counts <100 9 109/L or albumin
levels <3.5 g/dl at baseline were at increased risk for
serious bacterial infections, hepatic decompensation,
death and the frequency of Grade 3 anaemia was high
(4–13%) with frequent need for transfusions (6–18%)
and erythropoietin (46–57%) (6, 7).
In summary, HCV GT1-infected patients with cirrho-
sis with surrogate markers of portal hypertension or
impaired liver function at baseline achieved high SVR
rates with 3D + RBV, and treatment was well tolerated.
Patients with GT1a infection and indicators of portal
hypertension may benefit from extending treatment to
24 weeks, whereas treatment duration did not impact
SVR rates in GT1b-infected patients. The 3D + RBV reg-
imen is a promising treatment approach in these partic-
ularly vulnerable patient populations.
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